Analysts Expect Keryx Biopharmaceuticals (KERX) Will Announce Earnings of -$0.15 Per Share

Analysts expect that Keryx Biopharmaceuticals (NASDAQ:KERX) will post earnings per share (EPS) of ($0.15) for the current quarter, according to Zacks. Three analysts have provided estimates for Keryx Biopharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.13) and the lowest estimate coming in at ($0.16). Keryx Biopharmaceuticals reported earnings of ($0.21) per share during the same quarter last year, which suggests a positive year over year growth rate of 28.6%. The business is expected to report its next quarterly earnings report on Thursday, July 26th.

According to Zacks, analysts expect that Keryx Biopharmaceuticals will report full-year earnings of ($0.56) per share for the current financial year, with EPS estimates ranging from ($0.61) to ($0.50). For the next financial year, analysts expect that the company will post earnings of ($0.09) per share, with EPS estimates ranging from ($0.18) to $0.14. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for Keryx Biopharmaceuticals.

Keryx Biopharmaceuticals (NASDAQ:KERX) last released its earnings results on Friday, May 11th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of ($0.18). The company had revenue of $21.75 million for the quarter, compared to analyst estimates of $21.80 million. Keryx Biopharmaceuticals had a negative net margin of 230.00% and a negative return on equity of 10,954.62%.

KERX has been the topic of a number of research reports. Maxim Group set a $9.00 target price on shares of Keryx Biopharmaceuticals and gave the stock a “buy” rating in a report on Thursday, May 10th. BidaskClub lowered shares of Keryx Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 19th. Zacks Investment Research upgraded shares of Keryx Biopharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, April 11th. Finally, ValuEngine upgraded shares of Keryx Biopharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, May 2nd. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the stock. Keryx Biopharmaceuticals presently has an average rating of “Hold” and an average price target of $7.19.

Keryx Biopharmaceuticals remained flat at $$5.08 during mid-day trading on Monday, Marketbeat.com reports. 14,273 shares of the company’s stock were exchanged, compared to its average volume of 1,173,938. The firm has a market cap of $623.12 million, a price-to-earnings ratio of -5.77 and a beta of 2.63. Keryx Biopharmaceuticals has a 12 month low of $3.92 and a 12 month high of $8.38. The company has a debt-to-equity ratio of -3.96, a quick ratio of 1.87 and a current ratio of 2.66.

Institutional investors and hedge funds have recently made changes to their positions in the company. Teacher Retirement System of Texas acquired a new stake in shares of Keryx Biopharmaceuticals in the 4th quarter valued at $142,000. MetLife Investment Advisors LLC purchased a new position in shares of Keryx Biopharmaceuticals in the 4th quarter valued at $187,000. Cornerstone Capital Management Holdings LLC. purchased a new position in shares of Keryx Biopharmaceuticals in the 4th quarter valued at $192,000. Russell Investments Group Ltd. purchased a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at $201,000. Finally, Meridian Wealth Management LLC purchased a new position in shares of Keryx Biopharmaceuticals in the 1st quarter valued at $203,000. Institutional investors and hedge funds own 61.63% of the company’s stock.

Keryx Biopharmaceuticals Company Profile

Keryx Biopharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis.

Get a free copy of the Zacks research report on Keryx Biopharmaceuticals (KERX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Keryx Biopharmaceuticals (NASDAQ:KERX)

Receive News & Ratings for Keryx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply